基质金属蛋白酶在肾移植相关损伤中的表达及作用

董岩; 赵弘; 满江位; 杨立

doi:10.3969/j.issn.1674-7445.2020.06.018

基质金属蛋白酶在肾移植相关损伤中的表达及作用

doi: 10.3969/j.issn.1674-7445.2020.06.018

730030 兰州大学第二医院泌尿外科

基金项目:

甘肃省自然科学基金项目 17JR5RA237

详细信息

作者简介:
董岩，男，硕士，住院医师，研究方向为肾移植，Email：dongyansc2@163.com

通讯作者:
杨立，男，博士，主任医师，研究方向为肾移植，Email：yuze250@126.com

中图分类号: R617
计量
- 文章访问数: 121
- HTML全文浏览量: 56
- PDF下载量: 17
- 被引次数: 0
出版历程
- 收稿日期: 2020-07-27
- 网络出版日期: 2021-01-19
- 刊出日期: 2021-01-19

Expression and role of matrix metalloproteinase in injury related renal transplantation

Department of Urology, Lanzhou University Second Hospital, Lanzhou 730030, China

More Information

Corresponding author: Yang Li, E-mail:yuze250@126.com

摘要

摘要: 基质金属蛋白酶（MMP）是一大类蛋白酶，可切割或重塑细胞外基质（ECM）和细胞表面蛋白。MMP的活性受到多种细胞因子的调节，包括金属蛋白酶组织抑制因子（TIMP）、信号转导分子和细胞黏附分子等。最新的研究表明，MMP在许多急性和慢性肾病的病理生理过程中都有作用。本文就MMP的分类、在肾脏中的表达与分布及其在肾移植相关损伤中的作用作一综述。
- 基质金属蛋白酶 /
- 肾移植 /
- 细胞外基质 /
- 金属蛋白酶组织抑制因子 /
- 急性肾损伤 /
- 缺血-再灌注损伤 /
- 慢性移植肾肾病 /
- 炎症反应
Abstract: Matrix metalloproteinase (MMP) is a large class of proteases which can cut or reshape extracellular matrix (ECM) and cell surface proteins. The activity of MMP is regulated by a variety of cytokines, including tissue inhibitor of metalloprotease (TIMP), signal transduction molecules and cell adhesion molecules. The latest research shows that MMP has a role in the pathophysiology process of many acute and chronic kidney diseases. In this article, the classification, expression and distribution in the kidney of MMP and its role in injury related renal transplantation was reviewed.
- Matrix metalloproteinase /
- Renal transplantation /
- Extracellular matrix /
- Tissue inhibitor of metalloprotease /
- Acute kidney injury /
- Ischemia-reperfusion injury /
- Chronic allograft nephropathy /
- Inflammation

HTML全文

参考文献(34)

[1]	张洪海, 孙玉, 刘芳, 等.肝细胞癌患者血浆基质金属蛋白酶的检测及临床意义[J].临床肝胆病杂志, 2019, 35(4):825-829. DOI: 10.3969/j.issn.1001-5256.2019.04.023. ZHANG HH, SUN Y, LIU F, et al. Determination and clinical significance of plasma matrix metalloproteinase in patients with hepatocellular carcinoma[J]. J Clin Hepatol, 2019, 35(4):825-829. DOI: 10.3969/j.issn.1001-5256.2019.04.023.
[2]	CUI N, HU M, KHALIL RA. Biochemical and biological attributes of matrix metalloproteinases[J]. Prog Mol Biol Transl Sci, 2017, 147:1-73. DOI: 10.1016/bs.pmbts.2017.02.005.
[3]	MARINO-PUERTAS L, GOULAS T, GOMIS-RÜTH FX. Matrix metalloproteinases outside vertebrates[J]. Biochim Biophys Acta Mol Cell Res, 2017, 1864(11 Pt A):2026-2035. DOI: 10.1016/j.bbamcr.2017.04.003.
[4]	康玲玲, 高端敏.三七皂苷R1对心房颤动大鼠心肌炎症相关因子和金属基质蛋白酶表达的影响[J].中山大学学报(医学科学版), 2019, 40(6):921-929. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zsykdxxb201906016 KANG LL, GAO DM. Effects of notoginsenoside R1 on expression of myocardial inflammation-related factors and metalloproteinase in atrial fibrillation rats[J]. J Sun Yat-sen Univ (Med Sci), 2019, 40(6):921-929 http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zsykdxxb201906016
[5]	BAŁKOWIEC M, MAKSYM RB, WŁODARSKI PK. The bimodal role of matrix metalloproteinases and their inhibitors in etiology and pathogenesis of endometriosis (review)[J]. Mol Med Rep, 2018, 18(3):3123-3136. DOI: 10.3892/mmr.2018.9303.
[6]	MALEMUD CJ. Inhibition of MMPs and ADAM/ADAMTS[J]. Biochem Pharmacol, 2019, 165:33-40. DOI: 10.1016/j.bcp.2019.02.033.
[7]	MONTANER J, RAMIRO L, SIMATS A, et al. Matrix metalloproteinases and ADAMs in stroke[J]. Cell Mol Life Sci, 2019, 76(16):3117-3140. DOI: 10.1007/s00018-019-03175-5.
[8]	INKINEN KA, SOOTS AP, KROGERUS LA, et al. Fibrosis and matrix metalloproteinases in rat renal allografts[J]. Transpl Int, 2005, 18(5):506-512. DOI: 10.1111/j.1432-2277.2004.00053.x.
[9]	TOMITA M, KOIKE H, HAN GD, et al. Decreased collagen-degrading activity could be a marker of prolonged mesangial matrix expansion[J]. Clin Exp Nephrol, 2004, 8(1):17-26. DOI: 10.1007/s10157-003-0258-7.
[10]	OGBUREKE KU, FISHER LW. Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs)[J]. Kidney Int, 2005, 68(1):155-166. DOI: 10.1111/j.1523-1755.2005.00389.x.
[11]	KIM SS, SHIN N, BAE SS, et al. Enhanced expression of two discrete isoforms of matrix metalloproteinase-2 in experimental and human diabetic nephropathy[J]. PLoS One, 2017, 12(2):e0171625. DOI: 10.1371/journal.pone.0171625.
[12]	FANG X, SUN R, HU Y, et al. miRNA-182-5p, via HIF2α, contributes to arsenic carcinogenesis: evidence from human renal epithelial cells[J]. Metallomics, 2018, 10(11):1607-1617. DOI: 10.1039/c8mt00251g.
[13]	CARON A, DESROSIERS RR, LANGLOIS S, et al. Ischemia-reperfusion injury stimulates gelatinase expression and activity in kidney glomeruli[J]. Can J Physiol Pharmacol, 2005, 83(3):287-300. DOI: 10.1139/y05-011.
[14]	BERNAL F, HARTUNG HP, KIESEIER BC. Tissue mRNA expression in rat of newly described matrix metalloproteinases[J]. Biol Res, 2005, 38(2/3):267-271. DOI: 10.4067/s0716-97602005000200016.
[15]	NARULA S, TANDON C, TANDON S. Role of matrix metalloproteinases in degenerative kidney disorders[J]. Curr Med Chem, 2018, 25(15):1805-1816. DOI: 10.2174/0929867325666171205143441.
[16]	BONVENTRE JV. Mechanisms of ischemic acute renal failure[J]. Kidney Int, 1993, 43(5):1160-1178. DOI: 10.1038/ki.1993.163.
[17]	CARON A, DESROSIERS RR, BÉLIVEAU R. Ischemia injury alters endothelial cell properties of kidney cortex: stimulation of MMP-9[J]. Exp Cell Res, 2005, 310(1):105-116. DOI: 10.1016/j.yexcr.2005.07.004.
[18]	KUNUGI S, SHIMIZU A, KUWAHARA N, et al. Inhibition of matrix metalloproteinases reduces ischemia-reperfusion acute kidney injury[J]. Lab Invest, 2011, 91(2):170-180. DOI: 10.1038/labinvest.2010.174.
[19]	COVINGTON MD, BURGHARDT RC, PARRISH AR. Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14)[J]. Am J Physiol Renal Physiol, 2006, 290(1):F43-F51. DOI: 10.1152/ajprenal.00179.2005.
[20]	FU H, ZHOU D, ZHU H, et al. Matrix metalloproteinase-7 protects against acute kidney injury by priming renal tubules for survival and regeneration[J]. Kidney Int, 2019, 95(5):1167-1180. DOI: 10.1016/j.kint.2018.11.043.
[21]	MOSER MA, ARCAND S, LIN HB, et al. Protection of the transplant kidney from preservation injury by inhibition of matrix metalloproteinases[J]. PLoS One, 2016, 11(6):e0157508. DOI: 10.1371/journal.pone.0157508.
[22]	LAPLANTE A, LIU D, DEMEULE M, et al. Modulation of matrix gelatinases and metalloproteinase-activating process in acute kidney rejection[J]. Transpl Int, 2003, 16(4):262-269. DOI: 10.1007/s00147-002-0540-8.
[23]	RODRIGO E, LÓPEZ-HOYOS M, ESCALLADA R, et al. Circulating levels of matrix metalloproteinases MMP-3and MMP-2 in renal transplant recipients with chronic transplant nephropathy[J]. Nephrol Dial Transplant, 2000, 15(12):2041-2045. DOI: 10.1093/ndt/15.12.2041.
[24]	TURUNEN AJ, LINDGREN L, SALMELA KT, et al. Matrix metalloproteinase-9 and graft preservation injury in clinical renal transplantation[J]. Transplant Proc, 2015, 47(10):2831-2835. DOI:10.1016/j.transproceed. 2015.10.056.
[25]	MANKHEY RW, WELLS CC, BHATTI F, et al. 17beta-estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney[J]. Am J Physiol Regul Integr CompPhysiol, 2007, 292(2):R769-R777. DOI:10.1152/ajpregu. 00375.2006.
[26]	PALOMAR R, MAYORGA M, RUIZ JC, et al. Markers of fibrosis in early biopsies of renal transplants[J]. Transplant Proc, 2005, 37(3):1468-1470. DOI: 10.1016/j.transproceed.2005.02.051.
[27]	RACCA MA, NOVOA PA, RODRÍGUEZ I, et al. Renal dysfunction and intragraft proMMP9 activity in renal transplant recipients with interstitial fibrosis and tubular atrophy[J]. Transpl Int, 2015, 28(1):71-78. DOI: 10.1111/tri.12445.
[28]	MAZANOWSKA O, ZABIŃSKA M, KOŚCIELSKA-KASPRZAK K, et al. Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients[J]. Transplant Proc, 2014, 46(8):2636-2639. DOI: 10.1016/j.transproceed.2014.08.034.
[29]	HIRT-MINKOWSKI P, MARTI HP, HÖNGER G, et al. Correlation of serum and urinary matrix metalloproteases/tissue inhibitors of metalloproteases with subclinical allograft fibrosis in renal transplantation[J]. Transpl Immunol, 2014, 30(1):1-6. DOI:10.1016/j.trim.2013. 11.004.
[30]	KWIATKOWSKA E, DOMANSKI L, BOBER J, et al. Urinary metalloproteinases-9 and -2 and their inhibitors TIMP-1 and TIMP-2 are markers of early and long-term graft function after renal transplantation[J]. Kidney Blood Press Res, 2016, 41(3):288-297. DOI: 10.1159/000443431.
[31]	SCOZZI D, IBRAHIM M, MENNA C, et al. The role of neutrophils in transplanted organs[J]. Am J Transplant, 2017, 17(2):328-335. DOI: 10.1111/ajt.13940.
[32]	UCHIDA Y, FREITAS MC, ZHAO D, et al. The protective function of neutrophil elastase inhibitor in liver ischemia/reperfusion injury[J]. Transplantation, 2010, 89(9):1050-1056. DOI: 10.1097/TP.0b013e3181d45a98
[33]	YAO W, HAN X, GUAN Y, et al. Neutrophil elastase inhibitors suppress oxidative stress in lung during liver transplantation[J]. Oxid Med Cell Longev, 2019:7323986. DOI: 10.1155/2019/7323986.
[34]	JU YN, GENG YJ, WANG XT, et al. Endothelial progenitor cells attenuate ventilator-induced lung injury with large-volume ventilation[J]. Cell Transplant, 2019, 28(12):1674-1685. DOI: 10.1177/0963689719874048.